BIOGEN INC (BIIB)
US09062X1037 - Common Stock
BIOGEN INC
NASDAQ:BIIB (12/20/2024, 8:00:01 PM)
After market: 145.698 -0.77 (-0.53%)146.47
-0.92 (-0.62%)
Company Profile
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,570 full-time employees. The company has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. The company also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. The company commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.
Company Info
BIOGEN INC
225 Binney Street
Cambridge MASSACHUSETTS 02142
P: 17814642000
CEO: Michel Vounatsos
Employees: 7570
Website: https://www.biogen.com/
BIIB News
3 days ago - Market News VideoEMCOR Group Larger Than S&P 500 Component Biogen
3 days ago - ChartmillWondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Friday.
3 days ago - ChartmillWhat's going on in today's session: S&P500 moversJoin us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Friday as we examine the latest happenings in today's session.
3 days ago - Market News VideoFirst Week of BIIB February 2025 Options Trading13 days ago - Market News VideoOversold Conditions For Biogen (BIIB)18 days ago - Eisai Inc."LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
BIIB Twits
Here you can normally see the latest stock twits on BIIB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
